Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024

Damora Therapeutics, Inc.

Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.
Every 25 pre-split shares converted into 1 share; fractional shares rounded up to whole share.
Outstanding stock options and equity plans proportionately adjusted; trading symbol GLTO unchanged.
New CUSIP number is 36322Q 206; split effective after market close on August 29, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.